GlassScriptPhysician profile
Morgan Suzanne Rand
NPI 1528709987
$4,908.31
in general payments reported to CMS, 2019-2025
34 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2023: $676 · 2024: $1,602 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.16 |
| Education | $131.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $935.76 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $522.64 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $440.55 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $433.06 | 2024-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $283.38 | 2024-2025 | Krystexxa, Uplizna, Evenity |
| Glaxosmithkline, LLC. | $262.83 | 2022-2025 | Zejula, Jemperli, Benlysta |
| Ucb, INC. | $256.02 | 2024-2025 | Bimzelx |
| Impulse Dynamics (USA) INC. | $242.31 | 2023-2024 | Optimizer, Optimizer |
| Octapharma USA, INC. | $150.45 | 2025 | Octagam Immune Globulin (Human) |
| Merck Sharp & Dohme LLC | $150.45 | 2023-2024 | Verquvo, Keytruda, Lynparza |
| Pfizer INC. | $142.24 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $102.97 | 2024-2025 | Saphnelo, Imfinzi, Farxiga |
| Lexicon Pharmaceuticals, INC. | $102.78 | 2023-2024 | Inpefa |
| Seagen INC. | $99.95 | 2023 | |
| Eisai INC. | $90.04 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.76 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $66.92 | 2024 | Xarelto |
| Genmab U.S., INC. | $64.49 | 2022-2023 | Tivdak |
| Radius Health, INC. | $53.57 | 2024 | Tymlos |
| Myriad Genetic Laboratories, INC. | $43.94 | 2022-2023 | Myrisk |
| Aurinia Pharma U.S., INC. | $42.50 | 2024-2025 | Lupkynis |
| Iovance Biotherapeutics, INC. | $36.95 | 2024 | Amtagvi |
| Esperion Therapeutics, INC. | $34.11 | 2023-2024 | Nexletol |
| Invivyd INC | $33.94 | 2025 | Pemgarda |
| Actelion Pharmaceuticals US, INC. | $29.83 | 2024 | Uptravi, Opsumit |
| Fresenius Kabi USA, LLC | $29.26 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $26.29 | 2024 | Crysvita |
| Sandoz INC. | $25.57 | 2024 | Hyrimoz |
| Immunogen, INC. | $23.71 | 2023 | Elahere |
| Agios Pharmaceuticals, INC. | $23.58 | 2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $20.43 | 2023 | |
| Biocon Biologics INC | $20.12 | 2024 | Hulio |
| Mallinckrodt Hospital Products INC. | $17.83 | 2024 | Acthar |
| Lilly USA, LLC | $14.08 | 2024 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Rand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.